CME credits: 1.00

Valid until: 01-03-2025

Claim your CME credit at https://reachmd.com/programs/cme/first-line-targeted-therapies-for-ros1-fusion-positive-lung-cancers/18155/

This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.